MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Companies: Acquiring (M&A)
Crescent Biopharma, Inc.
Organization & Developments: Crescent Biopharma
Parents
Crescent Biopharma, Inc.
Children
*2024: Crescent is the fifth company to launch with assets discovered and developed by Paragon Therapeutics
*Crescent was founded to harness recent breakthroughs in immuno-oncology and antibody-drug conjugates that pave the way for a next generation of therapies for patients with solid tumors
2024: GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma
2024: In support of the acquisition, a syndicate of investors led by Fairmount, Venrock Healthcare Capital Partners, BVF Partners, and a large investment management firm, with participation from Paradigm BioCapital, RTW Investments, Blackstone Multi-Asset Investing, Frazier Life Sciences, Commodore Capital, Perceptive Advisers, Deep Track Capital, Boxer Capital Management, Soleus, Logos Capital, Driehaus Capital Management, Braidwell LP, and Wellington Management, has committed $200 million to purchase GlycoMimetics common stock and GlycoMimetics pre-funded warrants to purchase its common stock
Jumps
Finance & Acquisition: Crescent Biopharma
Key People: Crescent Biopharma